Results 31 to 40 of about 3,595 (167)
In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement
Antibiotics, 2023 Based on previous studies by our group in which we demonstrated that dalbavancin loaded in bone cement had good elution capacity for the treatment of biofilm-related periprosthetic infections, we now assess the anti-biofilm activity of dalbavancin and ...
Mar Sánchez-Somolinos +7 more
doaj +1 more source
Dalbavancin is thermally stable at clinically relevant temperatures against methicillin-sensitive Staphylococcus Aureus [PDF]
Journal of Bone and Joint Infection, 2023 Introduction: While the rate of orthopaedic infections has remained constant over the years, the burden on healthcare systems continues to rise with an aging population.
A. K. Hoyt +7 more
doaj +1 more source
The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa
Antibiotics, 2022 Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules, abscesses, and fistulas, localized to the areas of the folds where apocrine glands are present: the armpits, groin, inframammary region, and genital or
Elisa Molinelli +11 more
doaj +1 more source
Journal of Global Antimicrobial Resistance, 2021 : Objectives: Dalbavancin is a long-lasting lipoglycopeptide active against Gram-positive bacteria, especially methicillin-resistant staphylococci. Few data are available on dalbavancin use for treatment of prosthetic joint infections (PJIs).
Morgan Matt +15 more
doaj +1 more source
A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections
Antibiotics, 2023 Bone and joint infections (BJI) require prolonged antimicrobial treatment, leading to lengthy hospitalizations, high costs, the risk of nosocomial infections, and the development of antimicrobial resistance.
Dimitra Dimopoulou +3 more
doaj +1 more source
Multicenter clinical experience of real life Dalbavancin use in gram-positive infections
International Journal of Infectious Diseases, 2019 Dalbavancin, a lipoglycopeptide with prolonged half-life approved for the treatment of acute bacterial skin and soft tissue infections, can be used for the treatment of infections caused by gram-positive bacteria requiring long term treatment such as ...
S. Wunsch +8 more
doaj +1 more source
International Journal of Infectious Diseases, 2020 There is a paucity of literature on the use of dalbavancin, a long-acting lipoglycopeptide, in infective endocarditis. Existing case reports have investigated dalbavancin in endocarditis as a sequential treatment after clearance of bacteria from the ...
Aaron Hakim +3 more
doaj +1 more source
In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile
Frontiers in Microbiology, 2018 Background:Clostridium difficile (C. difficile) is a major nosocomial pathogen that colonizes in the human gut. Recently, the U.S. FDA approved three new antimicrobial agents against gram-positive bacteria: Tedizolid, Dalbavancin, and Ceftobiprole.
Dana Binyamin +9 more
doaj +1 more source
Frontiers in Microbiology, 2020 Microorganisms grown in biofilms are more resistant to antimicrobial treatment and immune system attacks compared to their planktonic forms. In fact, infections caused by biofilm-forming Staphylococcus aureus and Staphylococcus epidermidis are a large ...
Miglë Žiemytė +6 more
doaj +1 more source
International Journal of Infectious DiseasesObjectives: Due to its long half-life, dalbavancin offers benefits for long-duration treatments, especially osteoarticular and infective endocarditis (IE).
Milagros Suárez +9 more
doaj +1 more source